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We developed a neutrophil elastase-speciﬁc near-infrared ﬂuorescence imaging agent, which, combined with ﬂuorescence
molecular tomographic imaging, allowed us to detect and quantify neutrophil elastase activity in vivo, in real time, and
noninvasivelyinanacutemodeloflunginjury(ALI).SigniﬁcantlyhigherﬂuorescentsignalwasquantiﬁedinmicewithLPS/fMLP-
inducedALIascomparedtohealthycontrols,correlatingwithincreasesinthenumberofbronchoalveolarlavagecells,neutrophils,
and elastase activity. The agent was signiﬁcantly activated ex vivo in lung sections from ALI but not from control mice, and this
activation was ablated by the speciﬁc inhibitor sivelestat. Treatment with the speciﬁc inhibitor sivelestat signiﬁcantly reduced
lung signal in mice with ALI. These results underscore the unique ability of ﬂuorescence molecular imaging to quantify speciﬁc
molecular processes in vivo, crucial for understanding the mechanisms underlying disease progression and for assessing and
monitoring novel pharmacological interventions.
1.Introduction
Acute lung injury (ALI) and its more severe manifestation,
acute respiratory distress syndrome (ARDS) are life-threat-
ening conditions caused by a variety of insults such as
sepsis, trauma, pneumonia, inhalation of toxic chemicals or
fumes, and pulmonary aspiration [1]. In the US there are an
estimated yearly 190,000 new cases of ALI and 140,000 of
ARDS, with an overall pooled mortality rate of 43%. Each
year, cases of ALI alone require 3.6 million hospital days
and 2.15 million ICU days, a signiﬁcant burden in terms of
morbidity, mortality, length of hospitalization, and need for
rehabilitation [1, 2].
Animal studies have shown that both ALI and ARDS are
characterized by an alteration of the alveolar capillary barrier
which results in ﬂuid-ﬁlled airspaces, spread of pathogens,
loss of surfactant, and neutrophil inﬁltration. Activated
neutrophilsinturnreleasegrowthfactors,cytokines, reactive
oxygen species, and proteases, such as neutrophil elastase
(NE), contributing to tissue damage, organ dysfunction,
and further exacerbating the inﬂammatory process [3, 4].
NE, also known as leukocyte elastase or ELA2, is a 30-kD
glycoprotein chymotrypsin-like serine protease with broad
substrate speciﬁcity, capable of degrading many components
of the extracellular matrix such as collagen, elastin, ﬁbrin,
and ﬁbronectin. NE is stored at high concentrations in
neutrophil azurophil granules, together with proteinase 3
(PR3), cathepsin (Cat) G, and matrix metalloproteinase-
(MMP-) 9, and is also found at the surface of neutrophils
and free in the extracellular milieu [5–7]. Not only is NE
a signiﬁcant protease involved in ALI and ARDS, but also
in many other inﬂammatory processes such as emphy-
sema/chronicobstructivecysticﬁbrosis,chronicwoundheal-
ing, rheumatoid arthritis, as well as ischemia-reperfusion,
atherosclerosis, septicemia, and pneumonia [3].
Because of the high prevalence of ALI and ARDS, the
development of noninvasive techniques to spatiotemporally
visualize and quantify disease-associated NE in vivo is an
active area of research in many laboratories around the
world. Advances in optical imaging techniques will poten-
tially provide new tools for understanding the roles of NE in
disease onset and progression, as well as in the development
and assessment of speciﬁc NE inhibiting therapies. Clinical
applications of NE imaging may also help in ALI/ARDS2 International Journal of Molecular Imaging
diagnosis, staging of disease, and monitoring of treatment
eﬃcacy, as well as in assessing acute neutrophilia at other
sites of infection and inﬂammation. For example, a radiola-
beled aptamer-based inhibitor of NE coupled to 99mTc has
been used to image inﬂammation in a rat reverse passive
Arthus reaction model [8]a n da99mTc-labeled peptide NE
inhibitorwasusedtovisualizeinﬂammationandinfectionin
rhesus monkeys [9]. While established noninvasive imaging
modalities like PET and SPECT are sensitive and provide
functional information, their dependence on ionizing radi-
ation (with its related costs, complexity, shorter half-lives,
and radioactive material handling/disposal) limit their use.
Fluorescence oﬀers an alternative to the use of radiolabels,
but until recently ﬂuorescence detection was limited to the
assessment of surface ﬂuorescence by reﬂectance imaging.
Recentadvancesinopticalimagingledtothedevelopmentof
ﬂuorescence molecular tomography (FMT) [10, 11] imaging
which, paired with appropriate near infrared imaging agents,
has been used for imaging and quantiﬁcation of numerous
biological targets in 3 dimensions [12, 13]. FMT has been
used recently for imaging protease activity associated with
lung inﬂammation and treatment eﬃcacy in mouse models
of asthma [11, 14, 15], highlighting its capabilities in deep
tissue detection.
The present studies were undertaken to develop and val-
idate a novel NE-selective activatable near-infrared ﬂuores-
cent (NIRF) agent, Neutrophil Elastase 680 FAST (NE680),
for use in imaging and quantifying NE activity in mouse
models of neutrophil-mediated inﬂammation. Speciﬁcity of
the agent was conﬁrmed by screening with a panel of related,
and unrelated, proteases and by inhibition using the speciﬁc
NE inhibitor in vitro, in vivo, and in ex vivo tissue sections.
Most importantly, NE680 was used in vivo to image and
quantify NE activity associated with lung inﬂammation in
mice with ALI and response to treatment.
2.MaterialsandMethods
2.1. Fluorogenic Neutrophil Elastase 680 FAST Agent. The
ﬂuorogenic NE680 was provided by PerkinElmer (Neu-
trophil Elastase 680 FAST, Boston MA). Brieﬂy, two NIR
ﬂuorochromes (VivoTag-S680, PerkinElmer, Boston, MA)
were linked to both the C- and N-termini of the peptide
PMAVVQSVP, a highly NE-selective sequence over mouse
PR3 [16]. The substrate was further conjugated to a polymer
carrier at a ratio of 1 substrate per polymer molecule giving
the agent a ﬁnal molecular weight of approximately 40,000
daltons. UV-Vis absorbance and ﬂuorescence emission spec-
tra of the native and enzyme-activated agent were recorded
on a Cary 50 and Cary Eclipse spectrophotometers, respec-
tively, in 1× PBS using 665nm for ﬂuorescence excitation.
2.2. Mouse Plasma Stability. The agent was incubated in
normal mouse plasma (Innovative Research, Novi, MI)
diluted 1:4 in PBS, pH 7.40 with 1mM EDTA, at 37◦Cf o r
24h. The stability of the agent was analyzed by HPLC.
2.3. Pharmacokinetics. Twenty-four female retired breeder
CD-1 mice (age 12–16 weeks, Charles River Laboratories,
Wilmington, MA) received a bolus intravenous (i.v.) injec-
tionofNE680(2nmolinPBS).Terminalbloodsamples(n =
3 mice per time point) were collected by cardiac puncture
from each mouse (following carbon dioxide asphyxiation).
Plasma was collected by centrifugation (15,000rpm for
10min at 4◦C) in EDTA-containing tubes. Aliquots (50µL)
of each plasma sample were placed in Eppendorf tubes. Cold
methanol (150µL) was added and the tubes were vortexed
followed by centrifugation at 12,000rpm and 4◦Cf o r1 0
minutes. Approximately 110µL of the supernatants were
transferred to HPLC vials for analysis. Studies were con-
ducted in accordance with and approved by PerkinElmer’s
IACUC Institutional Animal Care and Use Committee
guidelines.
2.4. Agent Characterization by HPLC. HPLC analyses were
performed on a Waters model 2695 (Waters Corporation,
Milford, MA). The PDA, Waters model 2998, was set to
scan from 225nm to 800nm. The wavelength corresponding
to the absorbance maximum of the ﬂuorophore, 675nm,
was extracted from the PDA trace. The ﬂuorescence spec-
trophotometer was set to an excitation wavelength of 675nm
and emission was monitored at 693nm. Samples were
analyzed on a C4, 300 ˚ A, 5µm, 150 × 4.6mm HPLC column
(Phenomenex, Torrance, CA). The aqueous mobile phase
contained25mMammoniumformate,pH8.5.Sampleswere
elutedwithacetonitrileataﬂowrateof1mL/min.Agradient
of 15% to 85% organic provided suﬃcient resolution.
Standards were prepared with NE680 (0–2.5µM) in mouse
plasma. Standard curves had correlation coeﬃcients >0.98.
2.5. In Vitro Activation by Neutrophil Elastase and Related
Enzymes. Activation and protease selectivity of NE680 were
determined with NE and closely related enzymes including
PR3, Cat G, Cat B, and MMP-9. The assays were performed
with 0.05µM of enzyme and 0.5µM NE680 in the optimized
buﬀer and pH for each enzyme. Human NE was purchased
from Innovative Research (Novi, MI), recombinant mouse
NE, mouse Cat B, and active mouse Cat C from R and D
Systems (Minneapolis, MN), human neutrophil PR3 from
Athens Research and Technology (Athens, GA), and human
neutrophil Cat G and recombinant human MMP-9 from
BIOMOL International (Plymouth Meeting, PA). The reac-
tion buﬀers were as follows: for human NE, 100mM Tris
(pH 7.5); for mouse NE, 50mM Tris (pH 7.5), 1M NaCl,
0.05% Brij-35; for Cat B, 25mM MES (pH 5.0), 0.5mM
DTT (preactivation in 25mM MES pH 5.0, 5mM DTT for
15min at room temperature); for MMP-9, 50mM Tris (pH
7.5), 10mM CaCl2, 150mM NaCl, 0.05% Brij 35; for Cat G,
100mM Tris (pH 7.5), 1.6M NaCl; for human PR3, 100mM
Tris (pH 7.5), 500mM NaCl. Mouse NE was activated by
a c t i v em o u s eC a tCi n5 0m MM E S ,5 0m MN a C l ,p H 5 . 5a t
37◦Cfor2h.Reactionswerecarriedoutatroomtemperature
in 250µL in 96 well plates with black sides and bottom.
All the reactions were monitored at various time points
at excitation/emission wavelengths of 663/690nm with a
cutoﬀ at 665nm using a ﬂuorescence plate reader (Molecular
Devices, San Leandro, CA). The released ﬂuorescence isInternational Journal of Molecular Imaging 3
shown after subtracting background ﬂuorescence of the
agent without enzyme.
2.6. Inhibition of NE by Sivelestat. To conﬁrm the speciﬁcity
of NE680 activation by NE and not other proteases, in vitro,
ex vivo, and in vivo studies were performed in the absence or
presence of sivelestat (N-{2-[({4-[(2,2-dimethylpropanoyl)
oxy]phenyl}sulfonyl) amino]benzoyl} glycine sodium salt;
Tocris Bioscience, Ellisville, MO), a well-described speciﬁc
NE inhibitor [17]. The IC50 against human NE and human
PR3 were determined as described above using NE680
(0.5µM). Reactions were performed at room temperature
with a 30min preincubation of human NE or PR3 with seri-
ally diluted sivelestat. The IC50 represents the concentration
needed to achieve 50% inhibition of agent cleavage.
2.7. Acute Lung Injury Mouse Model. Acute lung inﬂamma-
tion was induced in mice according to published protocols
with slight modiﬁcations [18, 19]. Male CD-1 mice were
purchased from Charles River Laboratories (Wilmington,
MA) and used when they reached 8–10 weeks of age.
Mice were housed in environmentally controlled speciﬁc-
pathogen-free conditions with water and low-ﬂuorescence
mouse chow (Harlan Teklad, Madison, WI). All animal
experimental procedures were approved by PerkinElmer’s
Institutional Animal Care and Use Committee and were in
accordance with veterinarian requirements. On day 1, mice
were challenged intranasally (i.n.) with 100µgo fL P S( E .
coli 111:B4, Sigma, St. Louis, MO) solubilized in 40µL
PBS or PBS only. Eighteen hours later, mice received an
intranasal instillation of the chemotactic peptide N-formyl-
met-leu-phe (fMLP, Sigma, St. Louis, MO) at 200nM in
40µL PBS together with 4nmoles of NE680. To analyze the
relativecontributionofNEtotheactivationofNE680invivo,
groupsofmiceweretreatedi.n.withorwithoutNEinhibitor
sivelestat (5mg/kg 15min before fMLP and NE680 delivery).
2.8. Bronchoalveolar Lavage and Lung Collection. To validate
themodel,micewhichdidnotreceiveNE680,weresacriﬁced
after LPS (23h) and fMLP (5h) challenge, and the tracheas
were exposed through a midline incision. A sterile 22-gauge
needle connected to a 1mL syringe was inserted and used
to lavage the lungs in situ with a total of 1mL PBS. The
bronchoalveolar lavage (BAL) thus obtained was centrifuged
at 1000rpm for 5min. The pelleted cells were counted and
celltypeswereanalyzedundermicroscopyaftercytospinning
at 700rpm for 7min (Shandon Scientiﬁc) onto glass slides,
ﬁxing in methanol and staining with Giemsa for 5min.
The remaining BAL ﬂuids (BALF) were kept at −20◦C until
used for NE activity assays. After lavage, the lungs were
removed, rinsed with sterile saline, and homogenized at a
weight:volume ratio of 140mg per mL of 0.1M Tris pH 7.4.
After 3 cycles of freezing and thawing the lung lysates were
centrifuged at 14,000 for 30min at 4◦C. Supernatants were
kept at −20◦C until use for NE assays.
2.9. Neutrophil Elastase In Vitro Assays. NE activity in the
BALF and lung homogenates was measured using the well-
established MeOSu-AAPV-AMC substrate. One hundred µL
of BALF or lung lysates were incubated with MeOSu-AAPV-
AMC (0.1nM ﬁnal concentration) in 0.1M Tris pH 7.
Reactions were carried out in 250µL in 96 well plates with
black sides and bottom. All the reactions were monitored
at various timepoints at excitation/emission wavelengths of
400/505nm with a cutoﬀ at 450nm using a ﬂuorescence
plate reader (Molecular Devices, San Leandro, CA). The
released ﬂuorescence is shown after subtracting background
ﬂuorescence of the substrate only.
2.10. NE680 Activation in Lung Sections. To validate the
speciﬁcity of NE680 activation by NE present in lungs, mice
with lung inﬂammation and control healthy mice (which
had not received NE680) were euthanized by CO2 inhalation
and lungs were removed and snap frozen in OCT. Ten µm
lung sections were incubated with 1µM NE680 in the
absence or presence of increasing concentrations of sivelestat
(0.04–4µM) at 37◦C in a humidiﬁed incubator for 5h.
Fluorescence, as a measure of agent activation, was captured
under ﬂuorescence microscopy using appropriate ﬁlters
(Zeiss Axioskop 2 MOT Plus). DAPI was used as a nuclear
counterstain.
2.11.InVivoImagingandAnalysis. For invivo imaging, mice
were ﬁrst depilated using Nair and placed in a ﬂuorescence
molecular tomography (FMT) 2500 system (PerkinElmer,
Boston, MA) imaging chamber to which is delivered a
controlled amount of isoﬂurane/oxygen mixture keeping the
mice anesthetized. Three-dimensional regions of interest
(ROIs) were drawn around the chest area applying a univer-
sal threshold, equal to 40% of the mean concentration value
of ﬂuorescence in the LPS/fMLP mice (in nM). The total
amount (in picomole) of ﬂuorochrome was automatically
calculated relative to internal standards generated with
known concentrations of the appropriate ﬂuorochrome. For
each study, the mean ﬂuorescence of the LPS/fMLP group
was equaled to 100%, and then each mouse in that study was
normalized accordingly. Shown are the grouped results of 3
studies, as the percentage of LPS/fMLP Lung Fluorescence
(means ± S.E.M.).
2.12. Fluorescence Biodistribution. Immediately following
imaging, a cohort of mice were sacriﬁced (n = 3p e rg r o u p ) ,
organs excised, and imaged in reﬂectance mode using the
FMT 2500. The mean ﬂuorescence intensity was measured
after drawing an ROI around each organ. Data are expressed
as mean ﬂuorescence (in counts/energy) reported as means
± S.E.M.
2.13. Tissue Localization. Immediately following in vivo
imaging, mice were sacriﬁced, the intact lungs excised,
p e r f u s e dw i t hO C T ,a n ds n a pf r o z e ni nO C T .T e nm i c r o n
sections were prepared and imaged using ﬂuorescence
microscopy with appropriate ﬁlters (Zeiss Axioskop 2 MOT
Plus). DAPI was used as a nuclear counterstain. Comparable
sections were stained with Hematoxylin and Eosin using
standard protocols (Mass Histology, Worcester, MA).4 International Journal of Molecular Imaging
Substrate cleavage
Quenched ﬂuorochromes
PKM PKM
Activated ﬂuorochromes
Elastase
activation
Linker Linker Linker Linker
O OO O
(a)
Absorbance
Activated
Quenched
400 500 600 700 800 900
Wavelength(nm)
(
a
.
u
.
)
0.12
0.1
0 0. 8
0 0. 6
0 0. 4
0 0. 2
0
(b)
Quenched
Wavelength(nm)
Fluorescence
680 700 720 740
(
a
.
u
.
)
0
200
400
600
800
30×
Activated
(c)
Figure 1: Chemical design and properties of NE680. (a) The ﬂuorogenic peptide substrate is conjugated to a pharmacokinetic modiﬁer
(PKM) and ﬂanked by two NIR ﬂuorophores. Upon cleavage of the peptide by NE, the ﬂuorophores become ﬂuorescent. (b) Absorbance
spectra of the NE-activated ﬂuorescent form (dashed line) shows a bathochromic shift in the absorbance maximum relative to the native
autoquenched state (solid line). (c) The ﬂuorescence emission is increased more than 30-fold upon proteolytic activation with a maximum
at 690nm (excitation at 665nm).
2.14. Statistical Analysis. Data are presented as the means ±
S.E.M. Signiﬁcance analysis of diﬀerences between groups
was conducted using a two-tailed unpaired Student’s t-test
when comparing healthy controls and LPS/fMLP groups or
ANOVA when 3 or more groups were compared (StatView,
SAS Institute). Probability values of <5% were considered
signiﬁcant.
3. Results
3.1. Characterization of the Activatable NIR Fluorescent
Imaging Agent NE680. Figure 1(a) provides a schematic of
theNEsensingagent,NE680. Theconstructwasbuiltupona
highly speciﬁc NE substrate peptide sequence PMAVVQSVP
ﬂanked by two VivoTag-S680 NIR ﬂuorochromes. This
sequence has been shown to be highly selective for mouse
and human NE over mouse PR3. The discrete pair of closely
associated ﬂuorochromes is about 96–98% self-quenched,
reﬂecting static, groundstate quenching in the native state,
and exhibits a hypsochromic shift in absorbance of about
50nm (Figure 1(b)). The substrate was further conjugated
to a pharmacokinetic modiﬁer (PKM) comprising an
amphiphilic polymer to optimize the rate of blood clear-
ance (Figure 1(a)). Upon proteolysis of NE680 by NE, the
quenched ﬂuorochromes become highly ﬂuorescent, 30-
fold higher than background (Figure 1(c)). The doubly
labeled peptide was characterized by LCMS, UV-Vis and
ﬂuorescence spectroscopy prior to conjugation to the PKM.
Absorbance and emission spectra of the autoquenched and
enzyme-activated forms are shown in Figure 1(c).I n c u b a -
tion for 24h in mouse plasma at 37◦C conﬁrmed that the
agent is optically stable and remains quenched in a biological
environment (data not shown). The half-life of NE680 in
plasma, measured by collecting blood samples at various
time points after i.v. injection of the agent and analysis by
HPLC, was calculated to be t1/2 = 3h (data not shown).
3.2.NE680isPreferentiallyCleavedbyNeutrophilElastase. To
establish the enzyme selectivity of the agent, we compared
the activation of NE680 by both human and mouse NE
and a variety of closely related enzymes Cat G and PR3, as
well as MMP-9 and Cat B which are abundant proteases in
neutrophils. In vitro, NE680 was more rapidly and selectively
activated by human and mouse NE and human PR3 than
by mouse Cat B, human Cat G and MMP-9 (Figure 2(a)).
At 5h, cleavage by mouse NE was over 250-, 30-, and 10-
fold higher than by Cat B, MMP-9, and Cat G, respectively.
To distinguish NE activity from that of PR3 in subsequent
studies, the IC50 of sivelestat on NE680 activation was
determined for the two enzymes. NE was inhibited in a dose-
dependent fashion by sivelestat with an IC50 of 30nM while
itsinhibitionofhumanPR3wassigniﬁcantlylesspotentwith
an IC50 of 700nM (Figure 2(b)).
3.3. Experimental Acute Lung Injury. To investigate whether
NE680 could be used to image NE activity in vivo we ﬁrst
validated an acute lung inﬂammation model induced in
mice by intranasal challenge with LPS followed by fMLP.
In mice challenged with LPS/fMLP, the number of BAL
cells was signiﬁcantly higher than in control healthy mice
(Figure 3(a), P < 0.0001) and over 95% of the cells in
LPS/fMLP-induced mice were neutrophils when examinedInternational Journal of Molecular Imaging 5
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Figure 2: Activation of NE680 by NE and eﬀect of sivelestat. (a)
The agent (0.5µM) was activated in vitro by a panel of enzymes
(0.05µM) in optimized buﬀers and pH for each enzyme and the
ﬂuorescence monitored up to 5h in a ﬂuorescence microplate
reader. Released ﬂuorescence was obtained by subtracting the
ﬂuorescence of NE680 agent only from that of the NE680 in the
presence of enzymes. (b) Inhibition of human NE or PR3 by
sivelestat. Reactions were carried out in the presence of varying
concentrations of sivelestat. The IC50 represents the concentration
of sivelestat needed to achieve 50% inhibition of NE680 activation.
under microscopy (Figure 3(b), right panel). NE activity was
quantiﬁed in BALF and lung lysates using the commercially
available substrate MeOSu-AAPV-AMC. Signiﬁcantly higher
NE activity was detected in BALF (6-fold, P = 0.0165,
Figure 3(c)) from mice with ALI than controls. Lung lysates
from mice with ALI also exhibited higher NE activity (4-fold
ascomparedto lungsfromcontrolmice,P = 0.0032, data not
shown).
3.4. Speciﬁc Activation of NE680 in Lung Sections. Having
measured increases in elastase activity in the lungs and lung
extracts and BALF of LPS/fMLP-challenged mice, we deter-
mined whether NE680 could be activated in situ in lung
sections.Thus,10µmthickfrozenlungsectionsfromcontrol
and mice with ALI (not lavaged) were incubated with NE680
for 5h at 37◦Ct oa ll o ws u ﬃcient time for cleavage/activation
by secreted tissue proteases. Lungs from mice with ALI
showed strong ﬂuorescence, indicating activation of the
agent whereas there was little or no apparent ﬂuorescence in
control lungs (Figure 4). It should be noted that, when using
intranasalinstillation,itistechnicallyquitediﬃculttoensure
even distribution of LPS/fMLP across all lung surfaces due to
the small volume of instillation in each nostril and the vari-
ability of anesthesia eﬀects between mice. Thus, intranasal
instillation causes an uneven distribution of neutrophil-
mediated inﬂammation throughout the lung despite careful
andslowinstillation viabothnostrils.Notwithstanding these
caveats, the observed activation was suppressed in a dose-
dependent manner by increasing concentrations of the NE-
selective inhibitor sivelestat, with the higher doses of 0.4 and
4µM (at doses well below the IC50 for human PR3) almost
completely blocking NE680 activation. Taken together, the
inhibition of NE680 activation at diﬀerent doses of sivelestat
correlated well with the inhibition curves observed in vitro,
despite signiﬁcant experimental diﬀerences between the
tissue and biochemical assays.
3.5. In Vivo Real-Time Noninvasive Imaging and Quantiﬁca-
tion of NE680 Signal Correlates with NE Activity. The ability
of NE680 to be cleaved in vivo in a murine model of ALI was
substantiated by visualizing and quantifying the NIR signal
using quantitative molecular tomography with the FMT
2500. Fluorescence was readily detected in the lung region of
all mice with lung inﬂammation but not in control healthy
mice (Figure 5(a)). The ﬂuorescent signal was quantiﬁed
by drawing 3D ROIs in the chest area, encompassing the
lungs and applying a universal threshold equaling 40% of
the averaged mean ﬂuorescence of the LPS/fMLP mice. To
further assess in vivo the role of NE in the activation of
NE680, sivelestat was delivered i.n. using a therapeutic
dosing regimen initiated 18h after LPS (after the inﬂux of
neutrophils), prior to administration of NE680. The total
ﬂuorescence was signiﬁcantly higher in mice with ALI (n =
16;medianconcentrationof164nM)ascomparedtohealthy
controls (n = 12; 0nM) or mice treated with sivelestat
(n = 12; 73nM). To allow comparison between studies
varyinginthemagnitudeofsignalinpositivecontrolanimals
(range from 30–190pmols ﬂuorescence/lung), the data from
each study was normalized to the average ﬂuorescence in
the LPS/fMLP group. The data shown in Figure 5(b) reveals
that sivelestat, delivered i.n. just 15min prior to fMLP and
NE680 challenge signiﬁcantly decreased the activation of
the agent in mice with ALI (53.57 ± 10.34% versus 100 ±
13.2%, resp., P = 0.0144) while control mice had almost
no detectable ﬂuorescence (2.94 ± 1.51% of ALI mice, P
< 0.0001). These percentages correspond to averages of ∼
100pmol ﬂuorescence/lung in LPS/fMLP mice, with con-
trol mice showing <5pmol ﬂuorescence/lung. Fluorescence
biodistribution in the excised organs taken immediately6 International Journal of Molecular Imaging
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Figure 3: Bronchoalveolar cellular inﬁltration 24h after LPS challenge. Mice were challenged i.n. with 100µgo fL P Sf o l l o w e d1 8hl a t e r
by fMLP (200nM in 40µL PBS). Five hours later, mice were sacriﬁced, and bronchoalveolar lavage collected. (a) Cells were counted
using a hemocytometer. Data is shown as means ± S.E.M. (n = 5 mice per group) of a representative experiment. (b) Cells were spun
unto glass slides, stained with Giemsa and observed under microscopy. Shown are representative images from a control mouse and a
mouse with ALI. Note the presence of numerous neutrophils in the BAL of the ALI mouse. (c) NE activity in the bronchoalveolar lavage
ﬂuid (BALF) was measured using the MeOSu-AAPV-AMC ﬂuorometric substrate. Reactions were monitored at various time points at
excitation/emission wavelengths of 400/505nm using a ﬂuorescence microplate reader. Shown is the released ﬂuorescence after subtracting
background ﬂuorescence of the substrate only.
after imaging showed signiﬁcantly higher NE680 signal in
the lungs as compared to all other tissues (between 30-
to 170-fold higher signal, Figure 6). Cryostat sections of
the lungs showed much higher NIR ﬂuorescent signal in
the lungs of mice with ALI as compared to either controls
or ALI mice treated with sivelestat (Figure 7). Fluorescence
appeared to be mostly localized in and around the alveolar
walls, the interstitium as well as in the leukocyte inﬁltrates.
A small amount of signal was also found in the alveolar
lumen. Neutrophils inﬂux was mostly apparent in the ALI
and sivelestat groups while control mice exhibited normal
cellularity (Figure 7,b o t t o mp a n e l ) .International Journal of Molecular Imaging 7
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Figure 4: Eﬀect of sivelestat on the activation of NE680 ex vivo in lung sections. CD-1 mice were challenged with LPS and fMLP, lungs
collected 5h after fMLP and snap frozen. Vehicle-treated mice served as controls. Lung NE activity was assessed in situ by incubating lung
sections (10µm thick) with 1µM NE680 at 37◦C for 5h in the absence or presence of the NE inhibitor sivelestat. Fluorescent microscopy
images were captured with an acquisition time of 2.5s using a microscope equipped with xenon light source and Cy5.5 ﬁlters. Shown are
representative images at a ﬁnal 400× magniﬁcation. In blue, DAPI nuclear stain, in red, activated NE agent.
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Figure 5: Imaging and quantiﬁcation of NE680 activation in vivo. CD-1 mice were challenged i.n. with LPS and fMLP. A subset of mice was
also treated with the NE inhibitor sivelestat 15min prior to fMLP and NE680 (4nmoles i.n.) and mice imaged 5h later by FMT 2500. (a)
Representative volume rendering projections taken at the same color gating from control, LPS/fMLP and LPS/fMLP mice which had been
treated with sivelestat (5mg/kg i.n.). (b) The mean concentration of ﬂuorescence (in nM) was quantiﬁed in speciﬁc ROIs for the lung area
in control mice (N = 12), mice with ALI (N = 16), and Mice with ALI treated with sivelestat (N = 12) at a dose of 5mg/kg i.n.
4. Discussion
Acute neutrophilic inﬂammation is a hallmark of acute
lung injury and ARDS. Of the various enzymes secreted by
neutrophils at the sites of inﬂammation, NE stands out for
itspleiotropic eﬀects.Whileitplaysabeneﬁcialroleininnate
host defense, unbalanced NE can lead to organ damage and
dysfunction [3, 6]a n da ss u c hh a sb e e ni m p l i c a t e di naw i d e
range of pathological conditions such as sepsis, emphysema,
COPD, and cystic ﬁbrosis, in addition to ALI/ARDS [20].8 International Journal of Molecular Imaging
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Figure 6: Fluorescence biodistribution of activated NE680. Immediately after imaging, organs from 3 mice challenged with LPS/fMLP were
excised and imaged on the FMT 2500 system using the reﬂectance mode. Regions of interest were drawn around each organ using the FMT
software and the mean ﬂuorescence (Counts/Energy) determined. Shown are means ± S.E.M. Insert shows an image of the ﬂuorescence
detected in diﬀerent organs of a representative ALI mouse.
Given its well-documented deleterious and cytotoxic nature,
a speciﬁc imaging agent would prove invaluable for under-
standing the biological functions of NE and the development
of NE inhibitors. In this report we describe the use of a newly
developed speciﬁc NE molecular imaging agent, NE680, to
detect and quantify NE activity in vivo, in real time and
noninvasively in a mouse model of ALI. Because speciﬁcity
was of key importance, the substrate sequence used to
construct the imaging agent was chosen to be rapidly and
selectively cleaved by NE while remaining resistant to other
proteases including mouse PR3 [16]. Both PR3 and NE are
abundant serine proteases (approximately 100ng PR3/106
cells, 150ng–3µg NE/106 cells) [21, 22]w i t hp o t e n t i a l l y
overlapping substrates. In addition, it has been reported that
mouse and human PR3 exhibit diﬀerent species speciﬁcities
based on the analysis of 3D models [16]. The main diﬀerence
betweenmouseandhumanPR3wasfoundtoresideintheS2
subsite and the fact that mouse PR3 has a more negative net
charge than human PR3. Based on these observations which
set the precedence for species-speciﬁc sequences, NE680 was
designed with a high likelihood of preferential cleavage by
NE (both mouse and human) and not by mouse PR3.
The ultimate goal of this study was to be able to visualize
and quantify NE activity in vivo, in real time and nonin-
vasively. To this end, we ﬁrst validated a well-known ALI
model induced by intranasal challenge with LPS and fMLP
which act synergistically to cause lung inﬂammation charac-
terized by massive neutrophil inﬁltration and degranulation
[18, 19, 23]. As expected, LPS/fMLP administration resulted
in a signiﬁcant increase in the number of BAL cells, partic-
ularly neutrophils (Figure 3(a)). The agent designed for NE
imaging, NE680, was developed with a speciﬁc NE-ac-
tivatable sequence ﬂanked by ﬂuorochromes placed in close
enough proximity to each other for eﬃcient self-quenching
of ﬂuorescence. This generated a ﬂuorescent-labeled agent
that remains optically silent in the non-activated state but
becomes ﬂuorescent upon cleavage of the connecting sub-
strate sequence. Speciﬁcally, NIR ﬂuorochromes were used
because the NIR spectrum provides maximal tissue pene-
tration and minimal absorption by physiological absorbers
suchashemoglobinorwater.Modiﬁcationsoftheagentwith
a PKM extended the plasma and tissue half-lives, allow-
ing NE680 to accumulate and activate in target tissues.
Direct delivery of NE680 i.n. to the airspaces of ALI and
control mice was performed to facilitate an optimal intra-
luminal readout of the airspaces. Additional studies using
intravenous administration of NE680 also showed eﬀective
imaging of inﬂamed lungs; however, somewhat increased
background ﬂuorescence was detected in control lungs,
attributed to extrapulmonary degradation/activation and
distribution to lung tissue (data not shown). This ﬁnding
of increased background signal with intravenous injection
was unique to pulmonary imaging and did not occur in
preliminary studies in wound healing and acute paw edema
models (data not shown).International Journal of Molecular Imaging 9
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Figure 7: Localization of activated NE680 ex vivo. Lungs were snap frozen in OCT for ﬂuorescence microscopy. The distribution of NIR
ﬂuorescence was determined using ﬂuorescence microscopy. Digital images were captured using appropriate ﬁlters for DAPI, and the near-
infrared agent. In the top panel, the distribution of activated NE680 is shown in red, nuclei are counterstained with DAPI (blue). Final
magniﬁcation 200×. Bottom panel shows comparable sections taken from the same specimens showing increased cell inﬁltration in the lung
of mice with ALI and ALI treated with sivelestat as compared to controls.
The ﬂuorescence signal emitting from the lungs was
easily detected and quantiﬁed using FMT imaging. Three-
dimensional ROIs drawn around the lungs allowed cal-
culation of the local concentration in nM and total
amount, in pmol, of activated NE680 present. Signiﬁcantly
higher NE680 activation, proportional to increased levels
of NE activity (as determined by an independent method,
Figure 3(c)), was quantiﬁed in the lungs of ALI mice as com-
pared to controls which had barely detectable ﬂuorescence
(Figure 5). Excision of tissues following in vivo imaging
showed signiﬁcant ﬂuorescent signal in lungs as assessed by
reﬂectance NIRF imaging. An uneven distribution of
neutrophil-mediated inﬂammation throughout the lung
following intranasal instillation was seen despite careful and
slow instillation via both nostrils; the gastrointestinal tract
also contained ﬂuorescence which is linked to the agent
administration technique [24]. Nevertheless, analysis of the
lung sections revealed signiﬁcantly higher ﬂuorescent signal
from activated NE680 in the lungs from mice with ALI
(Figure 7). It must be noted that lungs were inﬂated with
OCT to avoid collapse during freezing and this could have
resulted in BAL cells and ﬂuid (and thus activated NE680)
being diluted and/or ﬂushed from the alveolar spaces.
Notwithstanding this caveat, H and E sections further con-
ﬁrmed the presence of neutrophils in the inﬂammatory lung
tissue with ALI and revealed that the distribution of acti-
vated NE680 ﬂuorescent signal is associated with inﬁltrated
neutrophils within the lung (Figure 7)b u ti sa l s of o u n di n
the interstitium and lumen. Neutrophil inﬁltration was also
apparent in the sivelestat group but was absent in the control
group as shown on the bottom panels of Figure 7 with H
and E staining. Neutrophil inﬂux was not inhibited with this
single sivelestat treatment protocol and thus, the readout is
truly a mechanistic biomarker for elastase activity (not a
composite of eﬀects on enzyme and cell numbers).
To determine whether the activation signal of NE680
that we had quantiﬁed ex vivo and in vivo was due to NE
activity alone, a number of corroborating studies had to
be performed. In vitro, we could not verify the inability of
mouse PR3 to cleave NE680 because it is not commercially
available. However, the sequence used to construct NE680 is
known to be minimally cleaved by mouse PR3 [16]. As an
additional veriﬁcation of selectivity, we determined that the
known NE-speciﬁc inhibitor sivelestat potently blocked the
activation of NE680 by NE (IC50 = 30nM similar to what has
been reported previously) [17]w i t hl e s sp o t e n c yo nh u m a n
PR3(IC50 =700nM).Thisisalsoinagreementwithprevious
studies showing the higher selectivity of sivelestat towards
NE over trypsin, thrombin, plasmin, plasma kallikrein,
pancreas kallikrein, chymotrypsin, and Cat G [17]. We used
intact lung sections from ALI mice, tissue known to have
high numbers of neutrophils and secreted Cat G, NE, and10 International Journal of Molecular Imaging
PR3 proteases, to evaluate the activation and speciﬁcity of
NE680. In such ex vivo studies, NE680 ﬂuorescence was sig-
niﬁcantly inhibited by as little as 40nM sivelestat (Figure 4).
Since the agent’s cleavage site is the NE-speciﬁc substrate
PMAVVQSVP [16] and the IC50 of NE over human PR3 is
23-times lower, it is very likely that the dominant neutrophil
protease involved in NE680 activation is NE, and likely
not PR3 or other oﬀ-target proteases associated with lung
inﬂammation. Other studies, using lung tissue homogenates
were inconclusive and required high doses of sivelestat to
inhibit either NE680 or AAPV-AMC cleavage (data not
shown), suggesting that the homogenization procedure re-
leased unrelated tissue intracellular proteases not normally
seen extracellularly in ALI.
Inhibition of NE activity in vivo was also achieved by
treatment with sivelestat, in agreement with previous reports
on its eﬃcacy in animal models of lung injury [25–29]. It is
important to note that in these and other reports, sivelestat
was administered before or at the time of the challenge (LPS,
ventilator-induced injury, and pneumococcal pneumonia),
and under these conditions sivelestat also inhibited the
migration of neutrophils into the site of injury. As a result,
it is diﬃcult to dissect the eﬀect of sivelestat on NE from
the eﬀect on neutrophil recruitment. In our studies, to better
demonstrate that sivelestat can directly inhibit NE activity,
and thus NE680 activation, the inhibitor was delivered 18h
after LPS challenge at a time when neutrophil migration had
alreadyoccurred. Thus, it can be inferred thatthe signiﬁcant,
although partial, inhibition of NE680 activation observed in
vivo (Figure 5(b)) is the direct result of the inhibition of NE
activity. The inability to completely block NE680 activation
in vivo is most likely due to the ineﬃciency of sivelestat
delivery and target coverage viai.n. administration, as nearly
complete inhibition was achieved in ALI lung frozen tissue
sections with as little as 40nM sivelestat. Taken together,
these interventional studies provide strong evidence that NE
activity in acute lung inﬂammation can be quantiﬁed and
monitored in vivo, in real time, and noninvasively.
5. Conclusion
In summary, we have developed a selective NE sensitive
ﬂuorescence activatable agent, NE680, and demonstrated its
ability to image and quantify NE activity noninvasively in a
model of ALI. To our knowledge, this is the ﬁrst molecular
NE imaging agent that can quantify increased NE activity
in lung inﬂammation and the eﬃcacy of selective therapy in
vivo. The combined in vitro and in vivo properties of NE680
and eﬃcacy in imaging LPS/fMLP-induced ALI suggest it
may be useful in other chronic neutrophil-driven disease
models, such as emphysema/chronic obstructive pulmonary
disease, cystic ﬁbrosis, acute neutrophilia, chronic wound
healing, rheumatoid arthritis, and infectious diseases. In
such models, which do not use fMLP to induce neutrophil
degranulation, the detection of the spontaneous release of
NE during inﬂammation may reveal subtleties in onset and
overall kinetics that may further enhance our understanding
of these diseases. Furthermore, by quantifying elastase-
mediated molecular processes, we believe that such a highly
speciﬁc agent combined with tomographic imaging will help
in the development of novel pharmacological interventions
in vivo. Application of such an agent in the context of
NIRF bronchoscopy would prove a valuable addition to
conventional imaging tools [30] in diagnosing, staging, and
monitoring of patients with lung inﬂammatory diseases or
cancer.
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